Arovella Therapeutics (ASX:ALA) Buyback Yield %: -17.49 (As of Jul. 04, 2026)


What is Arovella Therapeutics Buyback Yield %?

Arovella Therapeutics ASX:ALA Buyback Yield % is -17.49 as of Jul. 04, 2026. The stock has 1 warning sign investors should review. Among 744 Biotechnology companies, Arovella Therapeutics ranks worse than 64.38% on this metric.

Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.

Arovella Therapeutics's current buyback yield was -17.49%.

Arovella Therapeutics Buyback Yield % Historical Data

* Premium members only.

The historical data trend for Arovella Therapeutics's Buyback Yield % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arovella Therapeutics Buyback Yield % Chart

Arovella Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Buyback Yield %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -35.96 -40.61 -12.89 -9.93 -13.06

Arovella Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Buyback Yield % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -7.33 -9.93 -7.51 -13.06 -13.06

ASX:ALA vs VRTX, REGN, ALNY: Buyback Yield % Comparison

For the Biotechnology subindustry, Arovella Therapeutics's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arovella Therapeutics Buyback Yield % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arovella Therapeutics's Buyback Yield % distribution charts can be found below:

* The bar in red indicates where Arovella Therapeutics's Buyback Yield % falls into.


Arovella Therapeutics Buyback Yield % Calculation

Buyback yield is a measure of shareholder return.

Arovella Therapeutics's Buyback Yield for the fiscal year that ended in Jun. 2025 is calculated as

Buyback Yield=Net Issuance of Stock / Market Cap
=- (Repurchase of Stock + Issuance of Stock) / Market Cap
=- (-1.288 + 16.81) / 118.8566
=-13.06%

Arovella Therapeutics's annualized Buyback Yield for the quarter that ended in Dec. 2025 is calculated as

Buyback Yield=Net Issuance of Stock(TTM) / Market Cap
=- (Repurchase of Stock + Issuance of Stock) (TTM)** / Market Cap
=- (-1.297 + 15.889) / 111.710112
=-13.06%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

** If the quarter corresponds to the year-end period, we will use the annual Repurchase of Stock and Issuance of Stock data .

Frequently Asked Questions Learn more about Buyback Yield % →
What does a Buyback Yield % of -17.49 mean?
Arovella Therapeutics (ASX:ALA) has a Buyback Yield % of -17.49 as of Jul. 04, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Arovella Therapeutics and its competitors. According to the industry distribution chart, Arovella Therapeutics ranks #479 out of 744 companies in the Biotechnology industry, placing it in the top 64.4%.
Is Arovella Therapeutics' Buyback Yield % too high?
Arovella Therapeutics' current Buyback Yield % is -17.49. Based on the distribution chart, Arovella Therapeutics ranks #479 out of 744 companies in the Biotechnology industry, which is below the industry midpoint.
How does Arovella Therapeutics' Buyback Yield % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Arovella Therapeutics ranks #479 out of 744 companies for Buyback Yield %. This places Arovella Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Biotechnology company?
A good Buyback Yield % depends on the Biotechnology industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Arovella Therapeutics and its competitors. Arovella Therapeutics's current Buyback Yield % is -17.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arovella Therapeutics stock overvalued right now?
Arovella Therapeutics (ASX:ALA) has a current Buyback Yield % of -17.49. The current Buyback Yield % is -17.49. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Arovella Therapeutics (ASX:ALA), the current Buyback Yield % is -17.49 as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arovella Therapeutics Business Description

Other Exchanges E4NA:Germany
Address 84 Hotham Street, Corporate One, Preston, VIC, AUS, 3072
Arovella Therapeutics Ltd is a biotechnology company focused on developing its invariant natural killer T (iNKT) cell therapy platform from Imperial College London to treat blood cancers and solid tumours. The company's lead iNKT cell product is ALA-101. ALA-101 consists of iNKT cells engineered to produce a Chimeric Antigen Receptor (CAR) targeting CD19 on their surface. This CD19-targeting CAR allows the iNKT cells to find and kill tumour cells that express CD19.